Carbo/Paclitaxel v. Carbo/PLD as first line treatment for Ovarian Cancer
A recently study evaluated standard first line therapy – carboplatin plus paclitaxel – against carboplatin plus Doxil (PLD). This study of more than 800 women found that the use of Doxil was not superior to standard therapy, although the women in treatment had slightly higher PFS times and OS times. The study did conclude that treatment with Doxil front line may be an acceptable alternative to the current standard.
Read the abstract here